Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Lupin Ltd acquires Huminsulin from Eli Lilly to expand diabetes portfolio, offering a range of human insulin options.